PubMed:9125598 JSON TXT

Annnotations TAB JSON ListView MergeView

sentences

Preeclampsia

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":231,"end":243},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":257,"end":269},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":601,"end":613},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":745,"end":757},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":957,"end":969},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T6","span":{"begin":1246,"end":1258},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T7","span":{"begin":1681,"end":1702},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T8","span":{"begin":1815,"end":1827},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T9","span":{"begin":2168,"end":2180},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia.\nOBJECTIVES: Preeclampsia is characterized by maternal hypertension, proteinuria, edema, and shallow placental invasion. Insulin-like growth factor binding protein-1, abundant in maternal decidua, is believed to play a role in limiting trophoblast invasiveness. In this study we addressed the hypothesis that this binding protein is aberrantly expressed in preeclampsia. We also investigated circulating levels of insulin-like growth factor-I and insulin-like growth factor-II in subjects with severe preeclampsia compared with controls.\nSTUDY DESIGN: Insulin-like growth factor binding protein-1 was investigated by immunohistochemistry at the maternal-fetal interface of eight pregnancies complicated by severe preeclampsia and six controls between 21 and 34 weeks of gestation. Cell types were identified with use of cell-specific markers. Circulating levels of insulin-like growth factor binding protein-1, insulin-like growth factor-I, and insulin-like growth factor-II in 16 patients with severe preeclampsia and 29 controls at the same gestational age were determined by an immunoradiometric assay and correlated with clinical parameters. Data were analyzed by t test and Pearson's method.\nRESULTS: Insulin-like growth factor binding protein-1 was highly expressed on syncytiotrophoblasts, cytotrophoblasts, and decidual cells but not on placental fibroblasts. Immunostaining was greater at the maternal-fetal interface in severe preeclamptic patients compared with controls. Circulating insulin-like growth factor binding protein-1 levels in subjects with severe preeclampsia were 428.3 +/- 85.9 ng/ml compared with 76.6 +/- 11.8 in controls (p = 0.0007). Circulating insulin-like growth factor-I levels were 80.9 +/- 17.2 ng/ml compared with 179.4 +/- 28.2 ng/ml in controls (p = 0.0001). In contrast, insulin-like growth factor-II levels were not significantly different in the two groups. In subjects with severe preeclampsia insulin-like growth factor binding protein-1 levels correlated with diastolic blood pressure (r = 0.498, p 0.049) and aspartate transcarbamylase (0.621, p = 0.010).\nCONCLUSIONS: The abundance of insulin-like growth factor binding protein-1 at the maternal-fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow placental invasion observed in this disorder. Low circulating insulin-like growth factor-I and elevated insulin-like growth factor binding protein-1 levels may contribute to restricted placental and therefore fetal growth."}

Preeclampsia-compare

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":231,"end":243},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":257,"end":269},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":601,"end":613},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":745,"end":757},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":957,"end":969},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T6","span":{"begin":1246,"end":1258},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T7","span":{"begin":1681,"end":1693},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T8","span":{"begin":1815,"end":1827},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T9","span":{"begin":2168,"end":2180},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T10","span":{"begin":2465,"end":2477},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia.\nOBJECTIVES: Preeclampsia is characterized by maternal hypertension, proteinuria, edema, and shallow placental invasion. Insulin-like growth factor binding protein-1, abundant in maternal decidua, is believed to play a role in limiting trophoblast invasiveness. In this study we addressed the hypothesis that this binding protein is aberrantly expressed in preeclampsia. We also investigated circulating levels of insulin-like growth factor-I and insulin-like growth factor-II in subjects with severe preeclampsia compared with controls.\nSTUDY DESIGN: Insulin-like growth factor binding protein-1 was investigated by immunohistochemistry at the maternal-fetal interface of eight pregnancies complicated by severe preeclampsia and six controls between 21 and 34 weeks of gestation. Cell types were identified with use of cell-specific markers. Circulating levels of insulin-like growth factor binding protein-1, insulin-like growth factor-I, and insulin-like growth factor-II in 16 patients with severe preeclampsia and 29 controls at the same gestational age were determined by an immunoradiometric assay and correlated with clinical parameters. Data were analyzed by t test and Pearson's method.\nRESULTS: Insulin-like growth factor binding protein-1 was highly expressed on syncytiotrophoblasts, cytotrophoblasts, and decidual cells but not on placental fibroblasts. Immunostaining was greater at the maternal-fetal interface in severe preeclamptic patients compared with controls. Circulating insulin-like growth factor binding protein-1 levels in subjects with severe preeclampsia were 428.3 +/- 85.9 ng/ml compared with 76.6 +/- 11.8 in controls (p = 0.0007). Circulating insulin-like growth factor-I levels were 80.9 +/- 17.2 ng/ml compared with 179.4 +/- 28.2 ng/ml in controls (p = 0.0001). In contrast, insulin-like growth factor-II levels were not significantly different in the two groups. In subjects with severe preeclampsia insulin-like growth factor binding protein-1 levels correlated with diastolic blood pressure (r = 0.498, p 0.049) and aspartate transcarbamylase (0.621, p = 0.010).\nCONCLUSIONS: The abundance of insulin-like growth factor binding protein-1 at the maternal-fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow placental invasion observed in this disorder. Low circulating insulin-like growth factor-I and elevated insulin-like growth factor binding protein-1 levels may contribute to restricted placental and therefore fetal growth."}

UBERON-AE

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":432,"end":439},"obj":"http://purl.obolibrary.org/obo/UBERON_0002450"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":480,"end":491},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":1519,"end":1539},"obj":"http://purl.obolibrary.org/obo/UBERON_0000371"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":1541,"end":1557},"obj":"http://purl.obolibrary.org/obo/UBERON_0000319"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":2259,"end":2264},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia.\nOBJECTIVES: Preeclampsia is characterized by maternal hypertension, proteinuria, edema, and shallow placental invasion. Insulin-like growth factor binding protein-1, abundant in maternal decidua, is believed to play a role in limiting trophoblast invasiveness. In this study we addressed the hypothesis that this binding protein is aberrantly expressed in preeclampsia. We also investigated circulating levels of insulin-like growth factor-I and insulin-like growth factor-II in subjects with severe preeclampsia compared with controls.\nSTUDY DESIGN: Insulin-like growth factor binding protein-1 was investigated by immunohistochemistry at the maternal-fetal interface of eight pregnancies complicated by severe preeclampsia and six controls between 21 and 34 weeks of gestation. Cell types were identified with use of cell-specific markers. Circulating levels of insulin-like growth factor binding protein-1, insulin-like growth factor-I, and insulin-like growth factor-II in 16 patients with severe preeclampsia and 29 controls at the same gestational age were determined by an immunoradiometric assay and correlated with clinical parameters. Data were analyzed by t test and Pearson's method.\nRESULTS: Insulin-like growth factor binding protein-1 was highly expressed on syncytiotrophoblasts, cytotrophoblasts, and decidual cells but not on placental fibroblasts. Immunostaining was greater at the maternal-fetal interface in severe preeclamptic patients compared with controls. Circulating insulin-like growth factor binding protein-1 levels in subjects with severe preeclampsia were 428.3 +/- 85.9 ng/ml compared with 76.6 +/- 11.8 in controls (p = 0.0007). Circulating insulin-like growth factor-I levels were 80.9 +/- 17.2 ng/ml compared with 179.4 +/- 28.2 ng/ml in controls (p = 0.0001). In contrast, insulin-like growth factor-II levels were not significantly different in the two groups. In subjects with severe preeclampsia insulin-like growth factor binding protein-1 levels correlated with diastolic blood pressure (r = 0.498, p 0.049) and aspartate transcarbamylase (0.621, p = 0.010).\nCONCLUSIONS: The abundance of insulin-like growth factor binding protein-1 at the maternal-fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow placental invasion observed in this disorder. Low circulating insulin-like growth factor-I and elevated insulin-like growth factor binding protein-1 levels may contribute to restricted placental and therefore fetal growth."}

preeclampsia_genes

performance-test

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":2259,"end":2264},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":345,"end":354},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":1589,"end":1598},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":2575,"end":2584},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":2760,"end":2769},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":480,"end":491},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":432,"end":439},"obj":"http://purl.obolibrary.org/obo/UBERON_0002450"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":1519,"end":1539},"obj":"http://purl.obolibrary.org/obo/UBERON_0000371"},{"id":"PD-UBERON-AE-B_T9","span":{"begin":1541,"end":1557},"obj":"http://purl.obolibrary.org/obo/UBERON_0000319"}],"text":"Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia.\nOBJECTIVES: Preeclampsia is characterized by maternal hypertension, proteinuria, edema, and shallow placental invasion. Insulin-like growth factor binding protein-1, abundant in maternal decidua, is believed to play a role in limiting trophoblast invasiveness. In this study we addressed the hypothesis that this binding protein is aberrantly expressed in preeclampsia. We also investigated circulating levels of insulin-like growth factor-I and insulin-like growth factor-II in subjects with severe preeclampsia compared with controls.\nSTUDY DESIGN: Insulin-like growth factor binding protein-1 was investigated by immunohistochemistry at the maternal-fetal interface of eight pregnancies complicated by severe preeclampsia and six controls between 21 and 34 weeks of gestation. Cell types were identified with use of cell-specific markers. Circulating levels of insulin-like growth factor binding protein-1, insulin-like growth factor-I, and insulin-like growth factor-II in 16 patients with severe preeclampsia and 29 controls at the same gestational age were determined by an immunoradiometric assay and correlated with clinical parameters. Data were analyzed by t test and Pearson's method.\nRESULTS: Insulin-like growth factor binding protein-1 was highly expressed on syncytiotrophoblasts, cytotrophoblasts, and decidual cells but not on placental fibroblasts. Immunostaining was greater at the maternal-fetal interface in severe preeclamptic patients compared with controls. Circulating insulin-like growth factor binding protein-1 levels in subjects with severe preeclampsia were 428.3 +/- 85.9 ng/ml compared with 76.6 +/- 11.8 in controls (p = 0.0007). Circulating insulin-like growth factor-I levels were 80.9 +/- 17.2 ng/ml compared with 179.4 +/- 28.2 ng/ml in controls (p = 0.0001). In contrast, insulin-like growth factor-II levels were not significantly different in the two groups. In subjects with severe preeclampsia insulin-like growth factor binding protein-1 levels correlated with diastolic blood pressure (r = 0.498, p 0.049) and aspartate transcarbamylase (0.621, p = 0.010).\nCONCLUSIONS: The abundance of insulin-like growth factor binding protein-1 at the maternal-fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow placental invasion observed in this disorder. Low circulating insulin-like growth factor-I and elevated insulin-like growth factor binding protein-1 levels may contribute to restricted placental and therefore fetal growth."}